The core insight behind the approach is disarmingly simple. AlphaFold3 can model the structure of protein complexes, and researchers have increasingly used it to test whether two proteins that have never been shown to interact might nevertheless form a physical pair. The obvious way to apply this to an entire organism is to run the algorithm on every possible pair of proteins one at a time. But the arithmetic quickly becomes brutal. The number of possible pairwise interactions scales quadratically with the size of the proteome, so even a modest bacterium generates tens of thousands of candidate pairs, while the human proteome, with roughly 20,000 proteins, yields around 200 million. Running that many individual AlphaFold jobs is, as the authors of the accompanying commentary note, computationally intractable with realistic resources.

Todor and colleagues sidestepped the problem by refusing to play the game one pair at a time. Instead of enumerating every possible interaction, they grouped proteins into random pools, generally containing between 10 and 25 proteins, and submitted each pool to AlphaFold3’s free online server as a single job. Because AlphaFold3 models all proteins in an input simultaneously, each pooled run produces an all-versus-all comparison within that pool. The pools were designed so that every pair of proteins in the proteome appears together in at least one pool, guaranteeing that the full set of pairwise interactions gets modeled once all the pools have been processed. The logic that makes this work is that true interactions are rare: out of the vast number of possible pairs, only a small fraction are real, so the extra proteins packed into a pool are unlikely to interfere with the evaluation of genuine interactions.

The efficiency gains are striking. Compared with the traditional pairwise approach, pooling reduced the total number of AlphaFold jobs by 100-fold and improved the runtime by twofold. More surprisingly, the pooled approach also improved the overall accuracy of identifying true interactions. For a set of seven proteins, the enumerated pairwise strategy would require 21 separate AlphaFold runs, while the pooling strategy accomplishes the same coverage in just three. In a field where compute budgets routinely dictate the scope of a study, a method that is simultaneously cheaper, faster, and more accurate is a rare and welcome combination.

The organism chosen for the demonstration, Mycoplasma genitalium, is a free-living bacterium with one of the smallest known genomes, containing roughly 475 proteins and therefore 113,050 possible pairwise interactions. That scale is manageable enough to serve as a proof of principle, but it also highlights the limits of the current achievement. The human proteome’s roughly 200 million possible pairs remain far beyond what pooling alone can conquer. Other research groups have attacked the scaling problem from a different direction, prioritizing pairs of proteins that are most likely to interact based on independent evidence. Burke and colleagues, for example, produced AlphaFold2 models of confident protein pairs drawn from publicly available human protein interaction databases such as hu.MAP 2.0 and HuRI, while other teams have applied related strategies to core eukaryotic complexes and to systematic human interactome computations.

Prioritization, however, has an inherent dependency: it requires experimental interaction data to exist for the species being studied, or at least for a close relative. Non-model organisms, which include most of the bacterial and archaeal diversity on the planet, often lack such data entirely. This is precisely where the pooling approach shines, since it needs no prior knowledge to get started. Importantly, the two strategies are not in conflict. When experimental data are available, pooling and prioritization could in principle be combined in future efforts, using evidence-based filters to narrow the candidate space and pooled AlphaFold3 screening to evaluate what remains. For understudied organisms, pooling stands as a valuable new addition to the computational toolkit.

Why pooling improves accuracy remains an open question, and the authors have offered several hypotheses. One appealing idea involves competition among interactions. Because the pooled approach evaluates many potential interactions simultaneously, only the most confident interaction at any given protein interface will be selected in the final model. This competitive filtering could suppress false positives, particularly for promiscuous proteins that have a tendency to produce spurious predictions when considered in isolation. A deeper understanding of the mechanism behind the accuracy boost would be more than an academic curiosity; it would allow researchers to engineer protein pools deliberately, optimizing their composition to maximize predictive performance rather than relying on random assignment.

That same hypothesis, however, exposes a potential weakness. If AlphaFold3 prioritizes some interactions based on spatial constraints, then mutually exclusive interactions, in which two different proteins bind a third protein at the same interface, may cause one partner to be systematically favored over the other. Such exclusivity is common in nature and often underlies molecular functions that switch depending on cellular context. The severity of the problem depends on how many mutually exclusive interactions exist and on the size of the pools. With the current setup of 10 to 25 proteins per pool, the issue is likely to be rare, but if completeness becomes the explicit goal, or if pool sizes are increased to gain further efficiency, it will need to be addressed head-on.

There are also limitations inherited from AlphaFold3 itself. The algorithm depends on multiple sequence alignments to identify co-evolving pairs of amino acids, both within a single protein and between proteins in a complex, and it uses those co-evolutionary signals as distance constraints when building structural models. Proteins without sufficiently deep alignments suffer greatly in accuracy. In Mycoplasma genitalium, around 40 proteins, roughly 8 percent of the proteome, have limited sequence homology and appear to be found only in this species. As a result, nearly 18,000 protein pairs cannot be evaluated by this approach at all. That gap is more than a technical footnote, because species-specific proteins and their interactions may be responsible for the unique biology of the organism. Context-dependent interactions, such as those that form only under particular cellular conditions or in specific cell types, are similarly difficult for the method to discern.

Looking ahead, pooled screening offers an intriguing path toward detecting higher-order interactions, such as trimers and tetramers, which are often more biologically relevant than simple pairwise contacts. The obstacle is probabilistic: purely random pools make it unlikely that three or more proteins that genuinely interact in the cell will land in the same pool. Capturing all pairwise interactions through pooling is likely to be effective, but exhaustively screening all possible three-way combinations, roughly 18 million in Mycoplasma genitalium alone, will remain out of reach for quite a while unless pools are chosen intelligently rather than at random. Even so, the trajectory is clear. Todor and colleagues have brought the field measurably closer to the long-sought goal of complete, all-versus-all computational screening of protein interaction landscapes, for model organisms and neglected ones alike. The efficiency gains and the unexpected accuracy boost suggest that pooled AlphaFold screening will become an indispensable tool in a toolkit that is expanding at a remarkable pace.

Subject of Research: Proteome-wide prediction of protein-protein interactions using pooled AlphaFold3 screening

Article Title: Proteome-wide AlphaFold pool party

Article References: Drew, K. (2026). Proteome-wide AlphaFold pool party. Molecular Systems Biology, 22(4), 477-479. https://doi.org/10.1038/s44320-026-00198-6

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00198-6

Keywords: AlphaFold3, protein-protein interactions, Mycoplasma genitalium, structural biology, computational biology, proteome, deep learning, protein complexes, interactome, multiple sequence alignment, molecular systems biology, Proteome-wide

The research team, led by Tinworth and colleagues, undertook what is known as a proteome-wide genetic analysis. Rather than simply measuring proteins and looking for correlations with disease, the investigators exploited a powerful property of human genetics: each person’s blood protein levels are influenced by naturally occurring genetic variants. Because these variants are inherited randomly and fixed at conception, they are largely immune to the confounding that plagues ordinary observational studies. This approach, often called Mendelian randomization at the proteomic scale, allows scientists to ask whether a protein is merely a bystander in disease or whether it plays a genuine causal role.

The scale of the undertaking was considerable. The researchers drew on genetic and proteomic data from tens of thousands of individuals, quantifying thousands of proteins in blood plasma and then mapping genetic variants that predict the abundance of each one. They then cross-referenced these protein-encoding variants with genetic predictors of smoking behavior — including measures of smoking initiation, lifetime smoking burden, and smoking cessation — as well as with genetic predictors of ischemic heart disease risk. The goal was to find proteins whose genetically determined levels shift in response to smoking exposure and which, in turn, influence the likelihood of developing coronary artery disease.

Among the thousands of proteins screened, one stood out: asialoglycoprotein receptor 1, or ASGR1. This protein, produced primarily in the liver, is a receptor best known to cardiovascular researchers from a striking natural experiment. Individuals carrying loss-of-function mutations in the ASGR1 gene enjoy remarkably low levels of LDL cholesterol and a correspondingly reduced risk of coronary heart disease, a discovery that has already made ASGR1 a target of intense pharmaceutical interest. The new analysis adds a twist to that story: smoking appears to alter circulating levels of ASGR1, and this smoking-driven change may represent one pathway through which tobacco smoke raises the risk of ischemic heart disease.

The technical logic of the analysis deserves closer examination. In a conventional study, smokers differ from non-smokers in dozens of ways — diet, alcohol consumption, socioeconomic background, and countless other factors — making it nearly impossible to isolate the effect of smoking itself. Genetic instruments sidestep this problem. Variants that predict smoking behavior can be used as proxies for smoking exposure, and variants that predict protein levels can be used as proxies for protein abundance. By testing whether the smoking-linked variants associate with disease risk through the protein-linked variants, the researchers could trace a chain of causation from behavior to protein to pathology. Statistical methods such as two-step and mediation Mendelian randomization were applied to formalize this chain and to quantify how much of smoking’s cardiovascular effect might flow through ASGR1.

The results pointed to a meaningful mediating role. Smoking exposure was associated with changes in circulating ASGR1 levels, and genetically predicted alterations in ASGR1 were in turn linked to ischemic heart disease risk, consistent with the protein’s established role in lipid metabolism. While the analysis cannot claim that ASGR1 explains all — or even most — of smoking’s cardiovascular harm, it provides evidence that this receptor sits on a causal pathway connecting tobacco smoke to coronary disease. That distinction matters enormously for drug development. Biomarkers that merely correlate with disease often prove useless as therapeutic targets; proteins that causally mediate risk, by contrast, are precisely the molecules that intervention should aim at.

The findings also resonate with a broader shift in cardiovascular research. For decades, the link between smoking and heart disease was attributed largely to well-characterized mechanisms: carbon monoxide reducing oxygen delivery, oxidative stress damaging blood vessel walls, nicotine raising heart rate and blood pressure, and smoke constituents promoting inflammation and thrombosis. Proteomics adds a new layer to this picture, revealing that smoking leaves a detectable signature across hundreds of circulating proteins, some of which may actively participate in disease rather than simply marking it. Studies of this kind have previously uncovered mediators of inflammation, coagulation, and lipid transport, and the identification of ASGR1 extends that list into territory already being explored by the pharmaceutical industry.

Indeed, the therapeutic implications are among the most compelling aspects of the work. ASGR1 inhibitors are already in development as cholesterol-lowering agents, with several companies pursuing antisense oligonucleotide and antibody approaches designed to mimic the protective effect of natural loss-of-function mutations. If smoking acts partly by pushing ASGR1 in a harmful direction, then drugs that modulate the ASGR1 pathway could, in principle, blunt some of the cardiovascular damage inflicted by tobacco — even in people who continue to smoke or who quit too late to avoid all risk. Such an intervention would not excuse smoking, but it could offer a pharmacological safety net for the hundreds of millions of smokers worldwide who face elevated cardiac risk.

The authors and outside observers alike caution that important questions remain. Mendelian randomization rests on assumptions that can never be fully verified, and mediation analyses of this kind capture only the portion of an effect that flows through genetically influenced protein levels. Smoking damages the heart through many routes, and ASGR1 is unlikely to be the whole story. Validation in independent cohorts, experimental studies of how smoke constituents regulate ASGR1 expression, and ultimately clinical trials of ASGR1-targeted therapies in high-risk populations will all be needed before the biomarker can move from statistical association to clinical practice. Still, the study exemplifies how large-scale proteogenomic data can convert a diffuse behavioral risk factor into a concrete molecular hypothesis.

For the public, the message remains unchanged in its essentials: not smoking is still the single best thing a person can do for their heart. But for researchers and clinicians, the work offers something new — a specific, testable, and potentially druggable molecule that helps explain why cigarettes clog arteries. As proteomic datasets grow and genetic instruments sharpen, studies of this kind are expected to uncover further mediators linking lifestyle exposures to disease, gradually assembling a molecular map of how everyday behaviors shape long-term cardiovascular health. The identification of ASGR1 as a candidate link between smoking and ischemic heart disease is a notable waypoint on that map, and one that the cardiology community will be watching closely.

Subject of Research: Proteome-wide genetic analysis identifying ASGR1 as a molecular mediator linking smoking with ischemic heart disease

Article Title: Proteome-wide genetic analyses identify ASGR1 as a potential biomarker linking smoking with ischemic heart disease

Article References: Tinworth, A. C., Yao, P., Iona, A., Pozarickij, A., Von Ende, A., Millwood, I. Y., Walters, R. G., Clarke, R., Bragg, F., & Chen, Z. (2026). Proteome-wide genetic analyses identify ASGR1 as a potential biomarker linking smoking with ischemic heart disease. Nature Cardiovascular Research. https://doi.org/10.1038/s44161-026-00871-x

Image Credits: AI Generated

DOI: 10.1038/s44161-026-00871-x

Keywords: ASGR1, smoking, ischemic heart disease, proteomics, Mendelian randomization, biomarker, LDL cholesterol, cardiovascular risk, genetic analysis, coronary artery disease, Proteome-wide, genetic